Krumbholz Markus, Hofstadt-van Oy Ulrich, Angstwurm Klemens, Kleiter Ingo, Jarius Sven, Paul Friedemann, Aktas Orhan, Buchholz Grete, Kern Peter, Straube Andreas, Kümpfel Tania
Institute of Clinical Neuroimmunology, Ludwig Maximilian University, Max-Lebsche-Platz 31, 81377, Munich, Germany,
J Neurol. 2015 May;262(5):1379-84. doi: 10.1007/s00415-015-7766-8. Epub 2015 May 10.
Aquaporin-4 antibody (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is a rare but often severe autoimmune disease with median onset around 40 years of age. We report characteristics of three very-late-onset NMOSD (including complete NMO) patients >75 years of age, in whom this diagnosis initially seemed unlikely because of their age and age-associated concomitant diseases, and briefly review the literature. All three patients, aged 79, 82 and 88 years, presented with a spinal cord syndrome as the first clinical manifestation of AQP4-Ab-positive NMOSD. They all had severe relapses unless immunosuppressive therapy was initiated, and one untreated patient died of a fatal NMOSD course. Two patients developed side effects of immunosuppression. We conclude that a first manifestation of NMOSD should be considered even in patients beyond the age of 75 years with a compatible syndrome, especially longitudinally extensive myelitis. Early diagnosis and treatment are feasible and highly relevant. Special attention is warranted in the elderly to recognize adverse effects of immunosuppressive therapies as early as possible.
水通道蛋白4抗体(AQP4-Ab)阳性的视神经脊髓炎谱系障碍(NMOSD)是一种罕见但通常较为严重的自身免疫性疾病,发病年龄中位数约为40岁。我们报告了3例年龄超过75岁的极晚发性NMOSD(包括完全型NMO)患者的特征,由于他们的年龄以及与年龄相关的伴随疾病,最初似乎不太可能做出这种诊断,并简要回顾了相关文献。这3例患者年龄分别为79岁、82岁和88岁,均以脊髓综合征作为AQP4-Ab阳性NMOSD的首发临床表现。除非开始免疫抑制治疗,否则他们都会出现严重复发,1例未接受治疗的患者死于NMOSD的致命病程。2例患者出现了免疫抑制的副作用。我们得出结论,即使是75岁以上患有符合综合征的患者,尤其是纵向广泛脊髓炎患者,也应考虑NMOSD的首发表现。早期诊断和治疗是可行且高度相关的。对于老年人,需要特别注意尽早识别免疫抑制治疗的不良反应。